Onconova Therapeutics

04/03/2024

Apr 2, 2024 Onconova Therapeutics, Inc. And Trawsfynydd Therapeutics, Inc. Announce Business Combination To Form Traws Pharma, Inc, A Best-In-Class Virology And Oncology Company
https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-inc-and-trawsfynydd-therapeutics-inc

03/08/2024

Meena Arora (VP Global Medical Affairs & R&D) and Dr Victor Moyo (Chief Medical Officer) are pleased to be at the 25th European Congress on Gynaecological Oncology in Barcelona. They have found sessions informative as well as thought provoking and have had great discussions with experts in the field. If you would like to connect in Barcelona, please email us at [email protected].

03/08/2024

Onconova Therapeutics’ Rigosertib Poster Selected For AACR 2024
https://investor.onconova.com/press-releases
Poster Title: Rigosertib promotes anti-tumor activity of cancer cells via CETSA revealed novel targets and activates NLRP3-dependent inflammatory responses (2033/16)
Session: Microenvironment, Immunity, and DNA Repair in Therapeutic Response (PO.ET05.02)
Date/Time: Monday, April 8 9:00a-12:30p PT

02/29/2024

12/21/2023

The Onconova Management Team will be participating in the 13th Annual LifeSci Partners Corporate Access Event in San Francisco on January 8-9, 2024. Register using the link below to request an in-person meeting with us:

LifeSci Partners invites you to register for our 13th Annual Corporate Access Event Featuring more than 150 publicly trading and privately held companies from across the healthcare industry. Represented sectors…

12/12/2023

Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

12/10/2023

Dr Steve Fruchtman (CEO), Dr Victor Moyo (CMO) and Meena Arora (VP Global Medical Affairs and R&D) are proud to be at the 65th American Society of Haematology (ASH) in San Diego to present our collaborative research and discuss our research and development program. Please reach out at [email protected] if you would like to connect.

12/08/2023

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

12/07/2023

Meena Arora (Vice President Global Medical Affairs and R&D) and Dr Victor Moyo (Chief Medical Officer) are pleased to attend the San Antonio Breast Cancer Symposium (SABCS 2023) to connect with Oncology professionals for scientific discussions, present our collaborative research and learn from the insightful sessions to help us advance our science and research. Please reach out if you would like to connect with Meena and Victor in person in San Antonio this week.

11/28/2023

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference